AMP Starts Position in Cidara Therapeutics


Today, AMP started a position in Cidara Therapeutics (CDTX) for its hypothetical fund. Cidara is a clinical-stage biotechnology company developing infectious disease-focused drugs. Its lead asset is CD-101 IV, a Phase 2 echinocandid anti fungal to treat systemic Candida infections, which is expected to read out in late 2017/early 2018.

Read more about Cidara here.


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon